Abbott Laboratories (ABT)

Abbott Laboratories's Q·Score is 7.1/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $116.54 is 32% above current price. Key area to monitor: earnings contracting 20% year-over-year. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for ABT is $116.54, based on ratings from 24 Wall Street analysts. This is 32.2% above the current price of $88.18. Price targets are forward-looking estimates and not guarantees of future performance.

Abbott Laboratories (ABT) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 14.6×. The consensus analyst price target of $116.54 is 32% above the current price.

Abbott Laboratories's next earnings report is expected on approximately July 16, 2026.

Abbott Laboratories has a net profit margin of 13.9%, which is solid for most industries. Its gross margin stands at 56.5%, indicating a high-margin business model.

Abbott Laboratories currently offers a dividend yield of 2.86%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.

Abbott Laboratories is reporting modest revenue growth of 7.8%. However, earnings declined 19.7%, which warrants monitoring.

Abbott Laboratories has a debt-to-equity ratio of 0.65×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.39×, suggesting it should be monitored for near-term liquidity.